Asymchem Laboratories (stock code 06821) experienced abnormal fluctuations in its stock trading, with undisclosed matters that should have been disclosed but were not disclosed.
Kailaiying (06821) issued an announcement that the closing prices of the company's stock on March 31, 2026 and April 1, 2026 consecutively exceeded a cumulative deviation of 20%. According to relevant regulations of the Shenzhen Stock Exchange, this situation constitutes abnormal fluctuation in stock trading.
Asymchem Laboratories (06821) announced that the closing price of the company's stock on March 31, 2026 and April 1, 2026 had a cumulative deviation exceeding 20% for two consecutive trading days, which qualifies as abnormal stock price fluctuations according to the relevant regulations of the Shenzhen Stock Exchange.
The Board of Directors has confirmed that the company currently has no undisclosed matters or plans, negotiations, intentions, agreements, etc. related to the matter which should be disclosed in accordance with the Shenzhen Stock Exchange's "Stock Listing Rules" and other relevant regulations. The Board of Directors also has not received any information that would have a significant impact on the company's stock trading price and should be disclosed according to the Shenzhen Stock Exchange's "Stock Listing Rules" and other relevant regulations. There is no need to correct or supplement the information disclosed by the company earlier.
Related Articles

Far East Smarter Energy subsidiary won a total of 1.821 billion yuan in contract orders in March.

Noah Holdings (06686) spent approximately $44.84 million to repurchase 225,730 shares on March 31st.

Johnson & Johnson(JNJ.US) has obtained clinical approval in China for a new class 1 drug, intending to develop a treatment for multiple myeloma.
Far East Smarter Energy subsidiary won a total of 1.821 billion yuan in contract orders in March.

Noah Holdings (06686) spent approximately $44.84 million to repurchase 225,730 shares on March 31st.

Johnson & Johnson(JNJ.US) has obtained clinical approval in China for a new class 1 drug, intending to develop a treatment for multiple myeloma.






